Status:
TERMINATED
Treatment of Childhood Acute Lymphoblastic Leukemia
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborating Sponsors:
Boston Children's Hospital
Conditions:
Acute Lymphoblastic Leukemia
Eligibility:
All Genders
Up to 18 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to reduce the side-effects and discomfort of anti-leukemia therapy, to attain long-term control of the disease and to hopefully eradicate it.
Detailed Description
* Children with acute lymphoblastic leukemia (ALL) are treated somewhat differently depending upon on the relative risk of the leukemia recurring. For this study they are classified into "Standard Ris...
Eligibility Criteria
Inclusion
- Acute lymphoblastic leukemia, excluding known mature B-cell ALL
- \< 18 years of age
- Patients who are leukopheresed or exchanged are eligible for study only after completion of the pheresis or exchange transfusion
- Absence of a t(8,14) (q24; q32), t (8,22), t(2,8)
- Total bilirubin \< 1.4mg/dl
Exclusion
- Known HIV positive
- Prior steroid therapy within 30 days of diagnosis
- Septic shock
- Ongoing intracranial hemorrhage
- Clinical evidence of CNS or lung leukostasis
Key Trial Info
Start Date :
January 1 1996
Trial Type :
INTERVENTIONAL
End Date :
September 1 2006
Estimated Enrollment :
491 Patients enrolled
Trial Details
Trial ID
NCT00165087
Start Date
January 1 1996
End Date
September 1 2006
Last Update
December 28 2007
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Ochsner Clinic
New Orleans, Louisiana, United States, 70121
2
Maine Medical Center
Lewiston, Maine, United States, 04240
3
Children's Hospital Boston
Boston, Massachusetts, United States, 02115
4
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115